For the 100 years of its history, Fox Chase Cancer Center (FCCC) has been guided by a singular mission to reduce the burden of human cancer. Its 1904 hospital charter called for """"""""the study of the cause, treatment and prevention of cancer and for the dissemination of knowledge of these subjects. The treatment of cancer patients shall be administered without regard to race, creed or color."""""""" One hundred years later, the Center continues as one of the nation's comprehensive cancer centers, one of only a few free-standing centers in the country. During the last CCSG cycle, the Center has completed and opened a new 120,000 square foot Cancer Prevention Pavilion and finished construction of a new 17,000 square foot addition of a Clinical Investigation and Treatment Facility. We have made a major effort to expand our translational research and cancer-relevant science with the appointment of a Vice President for Translational Research, the development of a Translational Research Facility, and the use of all of our pilot project funds for translational research. Total institutional investment in the cancer research science, facilities, equipment, and buildings at Fox Chase during the last Core grant cycle was $173 million. We have recruited 35 new investigators, and of those here over 24 months, 22 of 24 (91%) have peer-reviewed funding totaling $7.42 million. Total peer-review funding at FCCC has increased from $32.7 million in 1999 to $49.3 million in 2004, a 50.7% increase, and total NCI funding has increased 42%. Growth in funding, space, and investigators has occurred in all three of the Institute's Divisions of Medical Science, Basic Science, and Population Science. We have also completed plans for a major expansion of the entire Center over the next 20 to 25 years which will result in tripling the number of Center investigators and quadrupling Center space. The first step in this process, the construction of the Cancer Research Pavilion with space for 15 to 20 new investigators, will take place during the next Core grant cycle. Developmental fund requests call for the recruitment of 29 new or replacement investigators, support for pilot projects, and investment in up to four new shared facilities. This Cancer Center Support Grant requests continued support for professional personnel, including senior and program leadership, administration, planning and evaluation, and developmental funds, as well as support for 11 established peer-reviewed Research Programs and 32 Shared Facilities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA006927-45S2
Application #
7498234
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-07-01
Project End
2010-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
45
Fiscal Year
2007
Total Cost
$116,355
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Fareed, Muhammad M; Eldib, Ahmed; Weiss, Stephanie E et al. (2018) A treatment planning comparison between a novel rotating gamma system and robotic linear accelerator based intracranial stereotactic radiosurgery/radiotherapy. Phys Med Biol 63:035029
Bleicher, Richard J (2018) Timing and Delays in Breast Cancer Evaluation and Treatment. Ann Surg Oncol 25:2829-2838
Bai, Tian; Chanda, Ashis Kumar; Egleston, Brian L et al. (2018) EHR phenotyping via jointly embedding medical concepts and words into a unified vector space. BMC Med Inform Decis Mak 18:123
Mehrazin, Reza; Dulaimi, Essel; Uzzo, Robert G et al. (2018) The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma. Ther Adv Urol 10:3-10
Tang, Baiqing; Lee, Hyung-Ok; An, Serim S et al. (2018) Specific Targeting of MTAP-Deleted Tumors with a Combination of 2'-Fluoroadenine and 5'-Methylthioadenosine. Cancer Res 78:4386-4395
Fang, Carolyn Y; Tseng, Marilyn (2018) Ethnic density and cancer: A review of the evidence. Cancer 124:1877-1903
Malik, R; Luong, T; Cao, X et al. (2018) Rigidity controls human desmoplastic matrix anisotropy to enable pancreatic cancer cell spread via extracellular signal-regulated kinase 2. Matrix Biol :
Giri, Veda N; Obeid, Elias; Hegarty, Sarah E et al. (2018) Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling. Prostate 78:879-888
Anari, Fern; O'Neill, John; Choi, Woonyoung et al. (2018) Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. Eur Urol Oncol 1:54-60
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739

Showing the most recent 10 out of 1280 publications